CriticalOpioid analgesic, phenylpiperidine class×Reversible MAO-A inhibitor (RIMA)
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, section 5.1). The combination with meperidine is contraindicated because of a higher risk of serotonin syndrome, and in animals moclobemide potentiates the effects of opiates (moclobemide SmPC, section 4.5). In patients who have received MAO inhibitors within 14 days, therapeutic doses of meperidine have occasionally caused unpredictable, severe and sometimes fatal reactions, and their mechanism is unclear (meperidine label, US Food and Drug Administration, FDA, section 5.6). According to the Spanish meperidine SmPC, acute excitation or depression of the central nervous system, with high or low blood pressure, can occur after an MAO inhibitor (section 4.3). Moclobemide inhibits MAO reversibly, and its half-life is about 3 hours (moclobemide SmPC, sections 5.1 and 5.2). Even so, meperidine is not given for 14 days after moclobemide, as after any MAO inhibitor (meperidine SmPC, section 4.3, and FDA meperidine label, section 4).
Symptoms
Serotonin syndrome with this combination presents with confusion, fever, seizures, loss of coordination (ataxia), overactive reflexes (hyperreflexia), muscle jerks (myoclonus) and diarrhoea (moclobemide summary of product characteristics, SmPC, section 4.5). According to the US Food and Drug Administration (FDA) meperidine label, reactions between meperidine and monoamine oxidase (MAO) inhibitors take different forms (section 5.6). Some resemble acute opioid overdose, with coma, severe respiratory depression, cyanosis and low blood pressure. Others resemble serotonin syndrome, with agitation, high temperature, diarrhoea, fast heart rate, sweating, tremor and impaired consciousness. In a third group, hyperexcitability, seizures, fast heart rate, very high fever and high blood pressure predominate (FDA meperidine label, section 5.6). Serotonin syndrome usually starts within several hours to a few days of combined use, but it may start later (FDA meperidine label, section 5.8).
Management
The combination is contraindicated. Meperidine is on the list of drugs contraindicated with moclobemide (moclobemide summary of product characteristics, SmPC, sections 4.3 and 4.5). The Spanish meperidine SmPC contraindicates monoamine oxidase (MAO) inhibitors and names moclobemide among the selective MAO type A inhibitors (meperidine SmPC, sections 4.3 and 4.5). The US Food and Drug Administration (FDA) meperidine label also contraindicates meperidine with MAO inhibitors or within 14 days of their use (sections 4, 5.6 and 7). Start meperidine no earlier than two weeks after the last dose of moclobemide (meperidine SmPC, section 4.3, and FDA meperidine label, sections 4 and 7). No document gives an interval for the opposite order, when moclobemide is started after meperidine. Switching to another opioid does not always remove the risk. Tramadol is also contraindicated with moclobemide. Morphine, fentanyl and codeine may need a dose adjustment, and buprenorphine needs caution because of the risk of serotonin syndrome (moclobemide SmPC, sections 4.3, 4.4 and 4.5). If serotonin syndrome is suspected, stop meperidine (FDA meperidine label, section 5.8) and, depending on severity, consider reducing the moclobemide dose or stopping moclobemide as well (moclobemide SmPC, section 4.4). Intravenous hydrocortisone or prednisolone have been used for severe reactions, with intravenous chlorpromazine added for high blood pressure and very high fever. The usefulness and safety of opioid overdose reversal agents in these reactions are unknown (FDA meperidine label, section 5.6).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Demerol injection (meperidine) prescribing information (2026)– FDA, DailyMed, Hospira, setid b31d1308-28c3-43f4-e0a6-2f3ed76b8975, revised 07/2026, sections 4, 5.6, 5.8 and 7
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Petidina, Dolantina 50 mg/ml (nº registro 24245), sección 4.3 (2026)– AEMPS, CIMA, nº registro 24245 (Kern Pharma), revisión 07/2026, secciones 4.3, 4.4 y 4.5